Buyback yield (TTM)
1.39%
Shareholder yield (TTM)
3.05%
5Y share count change
-16.9%
Buyback spend (TTM)
$300.00M
Cumulative buybacks
$12.59B
Key takeaways
- Quest Diagnostics (DGX) repurchased about $300.00M of stock over the trailing twelve months.
- Diluted share count is down 16.9% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 4.92× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +6.7% per year over the latest 5-year window.
- TTM repurchases used about 31% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Quest Diagnostics (DGX)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Quest Diagnostics (DGX)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Quest Diagnostics (DGX)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Quest Diagnostics (DGX)
Latest: $450.00M
Overview
Quest Diagnostics (DGX) most recent annual buyback spend stands at $450.00M (2025) – surged 198.0% year-over-year.
Quest Diagnostics buyback spend compound annual growth for the 2020–2025 (5 years) window is +6.7%, with mixed annual results across the window.
Quest Diagnostics buyback spend peaked at $2.20B in 2021; the latest annual figure is $450.00M in 2025 (79.5% below peak).
The record annual buyback spend stands at $2.20B, reached in 2021; the historical low of $0.00 was recorded in 1996.
Quest Diagnostics Buyback Spend 2025: $450.00M
In 2025, Quest Diagnostics reported buyback spend of $450.00M, surged 198.0% from 2024.
Quest Diagnostics Buyback Spend 2024: $151.00M
Quest Diagnostics buyback spend in 2024 was $151.00M, plunged 45.1% below 2023.
Quest Diagnostics Buyback Spend 2023: $275.00M
2023's buyback spend for Quest Diagnostics came in at $275.00M, plunged 80.5% below 2022.
Quest Diagnostics Buyback Spend 2022: $1.41B
Quest Diagnostics posted buyback spend of $1.41B in 2022, plunged 36.0% below 2021.
Quest Diagnostics Buyback Spend 2021: $2.20B
Quest Diagnostics buyback spend in 2021 was $2.20B.
See more financial history for Quest Diagnostics (DGX).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $450.00M | $88.00M | $362.00M | 2.34% | 0.11B | 0.0% | |
| 2024 | $151.00M | $88.00M | $63.00M | 0.90% | 0.11B | 0.0% | |
| 2023 | $275.00M | $77.00M | $198.00M | 1.78% | 0.11B | -4.2% | |
| 2022 | $1.41B | $77.00M | $1.33B | 7.96% | 0.12B | -7.8% | |
| 2021 | $2.20B | $79.00M | $2.12B | 10.42% | 0.13B | -5.9% | |
| 2020 | $325.00M | $97.00M | $228.00M | 2.02% | 0.14B | 0.0% | |
| 2019 | $353.00M | $56.00M | $297.00M | 2.47% | 0.14B | -2.2% | |
| 2018 | $322.00M | $61.00M | $261.00M | 2.84% | 0.14B | -0.7% | |
| 2017 | $465.00M | $79.00M | $386.00M | 3.47% | 0.14B | -1.4% | |
| 2016 | $590.00M | $69.00M | $521.00M | 4.65% | 0.14B | -2.1% | |
| 2015 | $224.00M | $52.00M | $172.00M | 2.20% | 0.14B | 0.0% | |
| 2014 | $132.00M | $51.00M | $81.00M | 1.36% | 0.14B | -5.2% | |
| 2013 | $1.04B | $28.00M | $1.01B | 13.27% | 0.15B | -4.4% | |
| 2012 | $200.00M | $50.30M | $149.70M | 2.16% | 0.16B | -0.1% | |
| 2011 | $935.00M | $71.90M | $863.10M | 10.17% | 0.16B | -9.6% | |
| 2010 | $750.00M | $53.90M | $696.10M | 8.60% | 0.18B | -5.6% | |
| 2009 | $499.99M | $75.10M | $424.89M | 4.60% | 0.19B | -4.2% | |
| 2008 | $254.00M | $70.60M | $183.40M | 2.58% | 0.20B | +0.4% | |
| 2007 | $145.66M | $0.00 | $145.66M | 1.42% | 0.20B | -2.1% | |
| 2006 | $472.32M | $0.00 | $472.32M | 4.61% | 0.20B | -2.9% | |
| 2005 | $390.16M | $0.00 | $390.16M | 3.82% | 0.21B | -3.2% | |
| 2004 | $734.58M | $0.00 | $734.58M | 7.68% | 0.21B | -1.7% | |
| 2003 | $257.55M | $0.00 | $257.55M | 3.41% | 0.22B | +8.4% | |
| 2002 | $0.00 | $0.00 | $0.00 | — | 0.20B | +2.0% | |
| 2001 | $1.00M | $0.00 | $1.00M | 0.01% | 0.20B | +3.5% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 0.19B | +39.0% | |
| 1999 | $1.10M | $0.00 | $1.10M | — | 0.14B | +12.5% | |
| 1998 | $13.00M | $0.00 | $13.00M | — | 0.12B | +4.1% | |
| 1997 | $0.00 | $0.00 | $0.00 | — | 0.12B | -1.1% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 0.12B | — |
- 2025$450.00M
- 2024$151.00M
- 2023$275.00M
- 2022$1.41B
- 2021$2.20B
- 2020$325.00M
- 2019$353.00M
- 2018$322.00M
- 2017$465.00M
- 2016$590.00M
- 2015$224.00M
- 2014$132.00M
- 2013$1.04B
- 2012$200.00M
- 2011$935.00M
- 2010$750.00M
- 2009$499.99M
- 2008$254.00M
- 2007$145.66M
- 2006$472.32M
- 2005$390.16M
- 2004$734.58M
- 2003$257.55M
- 2002$0.00
- 2001$1.00M
- 2000$0.00
- 1999$1.10M
- 1998$13.00M
- 1997$0.00
- 1996$0.00
Buybacks vs stock-based compensation for Quest Diagnostics (DGX)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 4.92×.
Buybacks vs dividends (share of cash returned) for Quest Diagnostics (DGX)
How Quest Diagnostics splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Quest Diagnostics, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $969.00M (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation